Abstract
The uPA system mainly comprises the urokinase-type plasminogen activator uPA, the cell-surface receptor uPA receptor and the inhibitor PAI-1. Its clinical and prognostic impact especially in breast cancer is well investigated. In this short report, we summarize the published data describing expression of uPA, PAI-1 and uPA receptor and their relevance to clinical and survival data in sarcomas underlining their impact as tumor biomarkers in this tumor type as well.
Original language | English |
---|---|
Pages (from-to) | 473-480 |
Number of pages | 8 |
Journal | Biomarkers in Medicine |
Volume | 7 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2013 |
Keywords
- PAI-1
- soft tissue and bone sarcoma
- uPA
- uPA receptor